UBS Group
PTHS

UBS Group’s Pelthos Therapeutics PTHS Stock Holding History

UBS Group’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.7K Buy
2,217
+1,453
+190% +$37.3K ﹤0.01% 7450
2026
Q1 		$16.1K Buy
764
+330
+76% +$7.83K ﹤0.01% 8087
2025
Q4 		$13.5K Buy
434
+297
+217% +$8.57K ﹤0.01% 8052
2025
Q3 		$3.84K Buy
137
+72
+111% +$1.75K ﹤0.01% 8999
2025
Q2 		$822 Sell
65
-35
-35% -$422 ﹤0.01% 9732
2025
Q1 		$1.41K Buy
+100
New +$1.71K ﹤0.01% 9510
2024
Q3 		– Sell
-19
Closed -$246 – 10160
2024
Q2 		$246 Buy
+19
New +$320 ﹤0.01% 9035

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

UBS Group's PTHS Position: Q2 2026 in Review

UBS Group increased its Pelthos Therapeutics (PTHS) stake by 190% in Q2 2026, buying an estimated $37.3K and bringing the position to 2,217 shares worth $62.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7450.

UBS Group first reported a position in PTHS in Q2 2024 and has held it in 7 quarters since. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • UBS Group held 2,217 shares of Pelthos Therapeutics worth $62.7K as of Q2 2026.
  • UBS Group bought 1,453 Pelthos Therapeutics shares in Q2 2026, an estimated $37.3K.
  • Pelthos Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7450 holding.
  • UBS Group first reported a position in Pelthos Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.